| Protein Name: | Lysozyme (P61626) |
|---|---|
| Gene Name: | LYZ |
| Description: | Lysozyme C precursor (EC 3 2 1 17) (1,4-beta-N-acetylmuramidase C) |
| PDB ID: | 133L |
| Protein Family: | |
| Protein Category: |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Captopril | Peripheral Leukopenia | Granulocyte aggregation was shown by the turbidimetric method and cellular activation was confirmed by the release of the granule associated enzyme lysozyme and beta-glucuronidase@which possibly mediated mechanism of peripheral leukopenia [ ADR Type 1 ] | A Captopril-induced granulocyte aggregation A possible complement mediated mechanism of peripheral leukopenia |
| doxorubicin hydrochloride nephrosis (AN) | Renal Tubular Injury | The urinary excretion of lysozyme and N-acetyl-glucosaminidase@ markers of renal tubular injury@ were significantly increased after 7 or 14 days in rats with doxorubicin hydrochloride nephrosis (AN) [ ADR Type 2 ] | Amelioration of glomerular injury in doxorubicin hydrochloride nephrosis by dimethylthiourea |
| Tobramycin | Nephrotoxicity | Treatment with TOB alone resulted in marked increases in the activities of Lysozyme@which leads to Effect of latamoxef (LMOX) against tobramycin (TOB)-induced nephrotoxicity [ ADR Type 2 ] | Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (3) Protective effect of latamoxef against tobramycin nephrotoxicity and its protective mechanism |
This panel provides information on drug category
| Toxicity | Source |
|---|